William Blair Investment Management LLC Has $105.25 Million Stake in GeneDx Holdings Corp. $WGS

Posted by Geri Gentry on May 24th, 2026

William Blair Investment Management LLC trimmed its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 33.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 809,210 shares of the company’s stock after selling 410,928 shares during the period. William Blair Investment Management LLC’s holdings in GeneDx were worth $105,246,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Jones Financial Companies Lllp increased its position in GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after buying an additional 186 shares during the last quarter. Quarry LP increased its position in GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in GeneDx during the fourth quarter worth $35,000. Gordian Capital Singapore Pte Ltd acquired a new position in GeneDx during the third quarter worth $65,000. Finally, AlphaQuest LLC increased its position in GeneDx by 70.8% during the third quarter. AlphaQuest LLC now owns 1,303 shares of the company’s stock worth $140,000 after buying an additional 540 shares during the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Kevin Feeley sold 392 shares of GeneDx stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total transaction of $25,554.48. Following the sale, the chief financial officer directly owned 34,942 shares of the company’s stock, valued at $2,277,868.98. This trade represents a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Casdin Capital, Llc bought 140,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $43.81 per share, for a total transaction of $6,133,400.00. Following the completion of the transaction, the director owned 3,507,164 shares of the company’s stock, valued at $153,648,854.84. This represents a 4.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 2,225,941 shares of company stock valued at $95,494,951 and have sold 104,028 shares valued at $7,377,165. 29.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

WGS has been the topic of several research analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Weiss Ratings raised GeneDx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Craig Hallum reaffirmed a “buy” rating and issued a $85.00 price target on shares of GeneDx in a research report on Tuesday, May 5th. Guggenheim lowered their price target on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Finally, BTIG Research lowered their price target on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $96.43.

View Our Latest Research Report on WGS

GeneDx Trading Down 0.0%

Shares of NASDAQ:WGS opened at $47.31 on Friday. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87. The company has a market cap of $1.40 billion, a P/E ratio of -17.65 and a beta of 2.06. The stock’s 50-day moving average is $59.72 and its 200-day moving average is $98.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09.

GeneDx (NASDAQ:WGS – Get Free Report) last released its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. During the same period last year, the business earned ($0.23) earnings per share. Equities research analysts predict that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

GeneDx Profile

(Free Report)

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.